Curie.Bio

ActiveVenture Capital

Website LinkedIn

Updated: Jan 22, 2026 ·

Financial History

Total Raised

N/A

Valuation

N/A

Investments Made

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Oct 1, 2025	Crosby	$20.0M Series A	—	Addition, Afore Capital, Altimeter Capital, Andreessen Horowitz, Contrary Capital, Khosla Ventures, Kleiner Perkins, Operator Partners, Saga, Sequoia Capital, Thrive Capital, Trust Ventures, Balaji Srinivasan, Elad Gil, Eric Wu, Karim Atiyeh, Max Mullen, Patrick Collison, Scott Belsky
Oct 1, 2025	Kalshi	$300.0M Series D	—	Andreessen Horowitz, Koch Fund, NEO, Operator Partners, Paradigm, Sequoia Capital, Elad Gil, Eric Wu, Henry Kravis, Justin Mateen, Karim Atiyeh, Max Mullen, Patrick Collison
Sep 1, 2025	Cardless	$60.0M Series C	—	Flexcap, Founder Collective, Operator Stack, Red Swan Ventures, Spark Capital, Team Ignite Ventures, Khaled Helioui, Nicky Goulimis
Sep 1, 2025	Pillar	$4.0M Seed	—	Daffy, Kleiner Perkins, Operator Partners, Rainfall Ventures, StartupGym, Streamlined Ventures, Gerald Parloiu, Oliver Jung, Portman Wills
Aug 1, 2025	Palabra.ai	$8.0M Seed	—	Andreessen Horowitz, Diaspora Ventures, Launch House Ventures, Operator Partners, Sequoia Capital, Seven Seven Six, Thrive Capital, Eduardo Alcalay, Elad Gil, Eric Wu, Javaughn Lawrence, Karim Atiyeh, Lucas Medola, Patrick Collison
Aug 1, 2025	Mithram Labs	$2.0M Seed	—	Bain Capital Ventures, Dash Fund, Fin Capital, F-Prime Capital Partners, Lightbank, Nyca Partners, Operator Partners, Pareto Holdings, Pear VC, Third Prime, Tidepool Labs, Y Combinator, Alexander Saint-Amand, Grant Miller, Nikhil Krishnan, Ralph Gootee, William Hockey
Jul 1, 2025	Small Door	$35.0M Venture Round	—	Alumni Ventures, Brand Foundry Ventures, Operator Partners, Primary Venture Partners, Toba Capital, Jonathan Neman, Yumin Choi
Jun 1, 2025	Kalshi	$190.0M Series C	—	Alumni Ventures, Andreessen Horowitz, Coinbase Ventures, Haun Ventures, Koch Fund, LGF, NEO, Hans Tung, Operator Partners, Paradigm, Sequoia Capital, Tusk Venture Partners, Amjad Masad, Elad Gil, Eric Wu, Henry Kravis, Justin Mateen, Karim Atiyeh, Max Mullen, Patrick Collison, Ron Pragides, Ryan Sarver, Ryan Tedder
Jun 1, 2025	Crosby	$6.0M Seed	—	Alt Capital, Jana Messerschmidt, Browder Capital, Factor[e] Ventures, Founders Fund, FTX Ventures, IVP, Khosla Ventures, Kleiner Perkins, Meritech Capital Partners, Mischief Venture Capital, Operator Partners, Pareto Holdings, Redpoint Ventures, Saga, Sequoia Capital, Summit Partners, TCV, The Hit Forge, Yext, Balaji Srinivasan, Christina Cacioppo, Dharmesh Shah, Dylan Field, Elad Gil, Eric Wu, Fidji Simo, Gokul Rajaram, Immad Akhund, Jason Lemkin, Jonathan Neman, Joshua Reeves, Julian Shapiro, Justin Mateen, Karim Atiyeh, Max Mullen, Parker Conrad, Patrick Collison, Scott Belsky, Sean Rad, Siqi Chen, Tony Xu
Apr 1, 2025	Superpower	$30.0M Series A	—	Acrew Capital, Adverb Ventures, AirAngels, AngelCube, ATX Venture Partners, Bain Capital Ventures, Canaan Partners, CP Ventures, Craft Ventures, Curious Capital, FJ Labs, Forerunner Ventures, Foundation Capital, Greylock, Inspired Capital, Kleiner Perkins, Klossy, monashees, Night Ventures, Offline Ventures, Operator Partners, Otherwise Fund, Pantera Capital, Pioneer Fund, REMUS Capital, RevTech Ventures, Serena Ventures, Seven Seven Six, Sound Ventures, Stage 2 Capital, Timespan Ventures, Torch Capital, Upfront Ventures, Version One Ventures, Abe Burns, Baron Davis, Brian Sugar, Casey Neistat, Evan Williams, Gokul Rajaram, Ian Borthwick, Jeffrey Wilke, Jonathan Widawski, Justin David Blau, Marissa Mayer, Mathilde Collin, Pir Granoff
Apr 1, 2025	Authorium	$8.0M Series A	—	Brewer Lane Ventures, Founder Collective, Govtech Fund, Operator Partners, Portage Ventures, Two Sigma Ventures
Mar 1, 2025	Norm AI	$48.0M Series A	—	Abstract Ventures, Alliance of Angels, Andreessen Horowitz, Atreides Management, Bain Capital Ventures, Bold Capital Partners, Chemistry VC, Commerce Ventures, Creative Juice, Exponent Founders Capital, Gradient Ventures, Khosla Ventures, Kindred Capital VC, Lightspeed Venture Partners, NFX, Operator Partners, The Community Fund, Uncorrelated Ventures, Gokul Rajaram, Jason Henrichs, Mark Cuban, Mengxi Lu, William Hockey
Feb 1, 2025	TrueFoundry	$19.0M Series A	—	AirAngels, Alt Capital, Alumni Ventures, Better Tomorrow Ventures, C2 Investment, Caffeinated Capital, CP Ventures, FJ Labs, Forerunner Ventures, Innovation Endeavors, INT3, Invariantes Fund, K2 Global, Long Journey Ventures, Operator Partners, Oyster Ventures, Pareto Holdings, Redpoint Ventures, Seaside Ventures, The Hit Forge, Trajectory Ventures, Trammell Venture Partners, Visible Ventures, Winklevoss Capital, Y Combinator, Aaron Levie, Adam D'Angelo, Amjad Masad, Aravind Bharadwaj, Azeem Azhar, Balaji Srinivasan, Claire Hughes Johnson, Evan Moore, Georges Harik, Greg Brockman, Jeff Hammerbacher, Kyle Vogt, Larry Summers, Logan Paul, Lukas Biewald, Marc Baghadjian, Mark Gillespie, Sahin Boydas, Scott Banister, Stephen Cole, Steve Aoki, Thomas Tull, Yair Weinberger, Yoav Amit
Nov 1, 2024	OpenYield	$7.0M Seed	—	Bain Capital Ventures, Dash Fund, Fin Capital, Nyca Partners, Operator Partners, Pareto Holdings, Third Prime, Alexander Saint-Amand, Grant Miller, William Hockey
Oct 1, 2024	Oshi Health	$60.0M Series C	—	Arkitekt Ventures, Bessemer Venture Partners, Flare Capital Partners, HealthQuest Capital, Oak HC/FT, Operator Partners, Jonathan Bush
Oct 1, 2024	Finix	$75.0M Series C	—	01 Advisors, 75 & Sunny, Acrew Capital, Act One Ventures, Alumni Ventures, American Express Ventures, Amplo, Bain Capital Ventures, Company Capital, DST Global, Homebrew, Inspired Capital, Luno Expeditions, MYASIAVC PTE LTD, Norwest Venture Partners, Operator Partners, Pareto Holdings, Partech Ventures, Precursor Ventures, Sarona Ventures, Sequoia Capital, Softbank Latin America Fund, The General Partnership, Treble Capital, Vamos Ventures, Vine Ventures LP, Emanuel Pleitez, Eric Wu, Henry Kravis, Jonas Huckestein, Marc Benioff, Tushar Garg
Oct 1, 2024	Zeal	$15.0M Series B	—	Andreessen Horowitz, Brewer Lane Ventures, FiDi Ventures, Founder Collective, Govtech Fund, Operator Partners, Portage Ventures, Spark Capital, Two Sigma Ventures, Jason Gardner, Omri Dahan
Oct 1, 2024	Healthie	$23.0M Series B	—	2048 Ventures, BoxGroup, Index Ventures, Lazerow Ventures, Maverick Capital, Stellar Capital, Susa Ventures, Techstars, Thrive Capital, Gautam Gupta
Sep 1, 2024	JOYA	$5.0M Seed	—	AirAngels, Comcast Ventures, Operator Partners, SoftBank Investment Advisers, Tiger Global Management, Twelve Below, Marc McCabe, Scott Belsky
Sep 1, 2024	Zenlytic	$9.0M Series A	—	Acrew Capital, Amino Collective, Bain Capital Ventures, Craft Ventures, Curious Capital, FJ Labs, High-Tech Gründerfonds, M13, Night Ventures, Operator Partners, REMUS Capital, Rethink Ventures, Serena Ventures, Seven Seven Six, Sound Ventures, Timespan Ventures, Version One Ventures, Abe Burns, Baron Davis, Brian Sugar, Casey Neistat, Gokul Rajaram, Ian Borthwick, Logan Paul, Pir Granoff, Rolf Schrömgens
Sep 1, 2024	Nym	$47.0M Venture Round	—	Addition, Bessemer Venture Partners, Ben Robbins, GV, Operator Partners
Sep 1, 2024	Hgen	$5.0M Seed	—	Acrew Capital, Bain Capital Ventures, Craft Ventures, Curious Capital, FJ Labs, Night Ventures, Operator Partners, REMUS Capital, Serena Ventures, Seven Seven Six, Sound Ventures, Stellar Capital, Sunset Ventures, Timespan Ventures, Version One Ventures, Abe Burns, Baron Davis, Brian Sugar, Casey Neistat, Gokul Rajaram, Ian Borthwick, Leore Avidar, Logan Paul, Pir Granoff
Jun 1, 2024	Roxom Global	$4.0M Seed	—	Alumni Ventures, Bolt, Cadenza Capital Management, Cygnus Capital, Draper Associates, Element Partners, Founders Fund, Haystack, Lightbank, Mantis VC, Next Play Ventures, NXTP Labs, Tiger Global Management, David Marcus, Marcelo Sampaio, Oliver Jung, Paulo Silveira, Philippe Teixeira da Mota, Rafael Larragoiti Lucas, Russell Fradin, Russ Fradin, Sam Altman
Jun 1, 2024	BirthFund	$1.0M Seed	—	Acrew Capital, Bain Capital Ventures, Banana Capital, Cherry Ventures, Craft Ventures, Curious Capital, Double Down, FJ Labs, Forerunner Ventures, Klossy, Makers Fund, Night Ventures, Operator Partners, REMUS Capital, Serena Ventures, Seven Seven Six, Sound Ventures, Timespan Ventures, Version One Ventures, Abe Burns, Aleksander Leonard Larsen, Baron Davis, Brian Sugar, Casey Neistat, Gokul Rajaram, Ian Borthwick, Jonathan Neman, Kevin Hart, Logan Paul, Nicolas Julia, Peter Sellis, Pir Granoff, Whitney Cummings, Yahya Mokhtarzada
Jun 1, 2024	Synthpop	$6.0M Seed	—	500 Global, Acrew Capital, Flexcap, Footwork, Founder Collective, Freestyle Capital, Index Ventures, K2 Global, Kearny Jackson, Kickstart Fund, Logos Labs, Long Journey Ventures, Offline Ventures, Peterson Ventures, Plug & Play Ventures, Prototype Capital, Redpoint Ventures, Sequoia Capital, SignalFire, Slack Fund, TQ Ventures, Unusual Ventures, Bradley Horowitz, Fareed Mosavat, Gabriel Jarrosson, Sahil Lavingia, Scott Belsky

Financial History

Total Raised

N/A

Valuation

N/A

Leadership Team

Key people at Curie.Bio.

Zach Weinberg

Investor

Leadership Team

Key people at Curie.Bio.

Zach Weinberg

Investor

Deep Dive

High-Level Overview

Curie.Bio is a founder-focused venture capital firm dedicated to helping scientists and entrepreneurs launch and scale biotech therapeutics companies. Its mission centers on lowering the barriers for founders by combining seed-stage investment with hands-on operational support, acting as both a financial backer and a “drug discovery co-pilot.” The firm invests primarily in early-stage biotech startups, with a focus on therapeutics, and provides founders with access to deep industry expertise, strategic guidance, and a network of top-tier drug hunters and vendors. By doing so, Curie.Bio aims to increase the likelihood of successful drug development and empower founders to retain control and ownership of their companies.

Origin Story

Founded in 2023 by Alexis Borisy, Christoph Lengauer, and Zach Weinberg, Curie.Bio emerged from the founders’ extensive experience in biotech venture capital and company building. Borisy and Lengauer previously helped launch and scale several successful biotech firms through Third Rock Ventures, while Weinberg brought experience from Alphabet (Google) and a track record of founding and scaling healthcare startups. The trio recognized a gap in the biotech ecosystem: many brilliant scientists lacked the operational know-how to navigate the complexities of launching and growing a company. Curie.Bio was created to bridge that gap, combining deep scientific expertise with a founder-first approach to venture capital.

Core Differentiators

Unique Investment Model: Curie.Bio blends seed-stage venture capital with an industry-grade therapeutics accelerator, offering both funding and hands-on operational support.
Network Strength: The firm boasts a team of over 80 full-time drug hunters, scientists, and industry veterans, many of whom have helped bring more than 70 drugs into clinical trials and achieved 12 regulatory approvals.
Track Record: The founding team and broader network have collectively raised over $500 million and played key roles in the exits of companies like Flatiron Health, Celsius Therapeutics, Relay Therapeutics, and Foundation Medicine.
Operating Support: Curie.Bio provides founders with guidance on target selection, hiring, data evaluation, regulatory strategy, and Series A fundraising, allowing scientists to focus on research while the firm handles the business side.

Role in the Broader Tech Landscape

Curie.Bio is riding the wave of a growing trend toward founder-centric, operator-led venture capital in biotech. As the cost and complexity of drug development continue to rise, there is increasing demand for investors who can provide not just capital but also deep operational expertise. Curie.Bio’s model is particularly well-suited to the current landscape, where scientific innovation is outpacing the ability of many founders to commercialize their discoveries. By lowering the barriers to entry and providing a robust support system, Curie.Bio is helping to democratize biotech entrepreneurship and accelerate the pace of medical innovation.

Quick Take & Future Outlook

Curie.Bio is poised to become a major force in the biotech venture ecosystem, setting a new standard for how early-stage therapeutics companies are launched and supported. As the firm continues to expand its portfolio and refine its operating model, it is likely to influence how other investors approach biotech venture capital, potentially inspiring a wave of similar “co-pilot” funds. The future of biotech innovation will increasingly depend on the ability of firms like Curie.Bio to empower founders with both capital and expertise, ensuring that groundbreaking science can translate into real-world therapies.

Sources

High-Level Overview

Origin Story

Core Differentiators

Unique Investment Model: Curie.Bio blends seed-stage venture capital with an industry-grade therapeutics accelerator, offering both funding and hands-on operational support.
Network Strength: The firm boasts a team of over 80 full-time drug hunters, scientists, and industry veterans, many of whom have helped bring more than 70 drugs into clinical trials and achieved 12 regulatory approvals.
Track Record: The founding team and broader network have collectively raised over $500 million and played key roles in the exits of companies like Flatiron Health, Celsius Therapeutics, Relay Therapeutics, and Foundation Medicine.
Operating Support: Curie.Bio provides founders with guidance on target selection, hiring, data evaluation, regulatory strategy, and Series A fundraising, allowing scientists to focus on research while the firm handles the business side.